Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Rhea-AI Summary

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 5th Annual NASH Investor Conference set for October 12, 2021, at 2:30 p.m. ET. The company is focused on developing therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, featuring a portfolio that includes three clinical-stage programs and a preclinical program. A live audio webcast of the presentation will be available on Terns’ investor relations page, with a replay archived for 30 days.

FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, today announced that management will be presenting at the H.C. Wainwright 5^th Annual NASH Investor Conference on Tuesday, October 12 at 2:30 p.m. ET.

A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns’ pipeline includes three clinical stage development programs including an FXR agonist, a VAP-1 inhibitor and a THR-β agonist, and a preclinical GLP-1 receptor agonist program. Terns is focused on developing combination therapies based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. For more information, please visit: www.ternspharma.com.

Contacts for Terns

Investors
Justin Ng
investors@ternspharma.com

Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com 

FAQ

What is Terns Pharmaceuticals presenting at the NASH Investor Conference?

Terns Pharmaceuticals will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021.

When is Terns Pharmaceuticals' presentation scheduled?

The presentation is scheduled for October 12, 2021, at 2:30 p.m. ET.

How can I listen to Terns Pharmaceuticals' presentation?

A live audio webcast of the presentation will be available on Terns' investor relations page.

What therapies is Terns Pharmaceuticals developing for NASH?

Terns is developing several therapies for NASH, including an FXR agonist, a VAP-1 inhibitor, and a THR-β agonist.

What is the significance of Terns Pharmaceuticals' NASH research?

Terns aims to develop combination therapies to address multiple disease processes in NASH, potentially improving clinical outcomes.